BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. Source
No articles found.
Global Pharma Labs, Inc. is a pharmaceutical company. The San Leandro, California...
Global Pharma Labs, Inc. is a pharmaceutical co...
Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of...
Arcturus Therapeutics is developing portfolio o...
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...
bluebird bio is pioneering gene therapy with pu...
Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage neuroscience company f...
Prothena Corporation plc (Nasdaq: PRTA) is a cl...
WinSanTorâs mission is simple-develop a drug that works. We recognize that there...
WinSanTorâs mission is simple-develop a drug ...
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and ...
Catalyst Pharmaceuticals is a biopharmaceutical...
20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...
20/20 GeneSystems, Inc. an early stage digital ...
Join the National Investor Network and get the latest information with your interests in mind.